Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation

Endothelial cell senescence contributes to chronic inflammation and endothelial dysfunction, while favoring cardiovascular disorders and frailty. Senescent cells acquire a pro-inflammatory secretory phenotype that further propagates inflammation and senescence to neighboring cells. Cell senescence c...

ver descrição completa

Detalhes bibliográficos
Autores: Shamoon, Licia, Espitia-Corredor, Jenaro A., Dongil, Pilar, Menéndez Ribes, Marta, Romero, Alejandra, Valencia Fernández, Inés, Díaz-Araya, Guillermo, Sánchez Ferrer, Carlos Félix, Peiró Vallejo, M. Concepción
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/710495
Acesso em linha:http://hdl.handle.net/10486/710495
https://dx.doi.org/10.1016/j.bcp.2022.115078
Access Level:acceso abierto
Palavra-chave:Resolvin E1
endothelial senescence
NLRP3 inflammasome
doxorubicin
interleukin 1β
vascular aging
Medicina
id ES_86bec604466dd23b567d36a737c19f4d
oai_identifier_str oai:repositorio.uam.es:10486/710495
network_acronym_str ES
network_name_str España
repository_id_str
spelling Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activationShamoon, LiciaEspitia-Corredor, Jenaro A.Dongil, PilarMenéndez Ribes, MartaRomero, AlejandraValencia Fernández, InésDíaz-Araya, GuillermoSánchez Ferrer, Carlos FélixPeiró Vallejo, M. ConcepciónResolvin E1endothelial senescenceNLRP3 inflammasomedoxorubicininterleukin 1βvascular agingMedicinaEndothelial cell senescence contributes to chronic inflammation and endothelial dysfunction, while favoring cardiovascular disorders and frailty. Senescent cells acquire a pro-inflammatory secretory phenotype that further propagates inflammation and senescence to neighboring cells. Cell senescence can be provoked by plethora of stressors, including inflammatory molecules and chemotherapeutic drugs. Doxorubicin (Doxo) is a powerful anthracycline anticancer drug whose clinical application is constrained by a dose-limiting cardiovascular toxicity. We here investigated whether cell senescence can contribute to the vascular damage elicited by Doxo. In human umbilical vein endothelial cells (HUVEC) cultures, Doxo (10–100 nM) increased the number of SA-β-gal positive cells and the levels of γH2AX, p21 and p53, used as markers of senescence. Moreover, we identified Doxo-induced senescence to be mediated by the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome, a key player of the immune innate system capable of releasing interleukin (IL)-1β. In fact, IL-1β itself mimicked the stimulatory action of Doxo on both NLRP3 activation and cellular senescence, while the pharmacological blockade of IL-1 receptors markedly attenuated the pro-senescence effects of Doxo. In search of additional pharmacological strategies to attenuate Doxo-induced endothelial senescence, we identified resolvin E1 (RvE1), an endogenous pro-resolving mediator, as capable of reducing cell senescence induced by both Doxo and IL-1β by interfering with the increased expression of pP65, NLRP3, and pro-IL-1β proteins and with the formation of active NLRP3 inflammasome complexes. Overall, RvE1 and the blockade of the NLRP3 inflammasome-IL-1β axis may offer a novel therapeutic approach against Doxo-induced cardiovascular toxicity and subsequent sequelaeElsevierDepartamento de FarmacologíaFacultad de Medicina20222022-05-10research articlehttp://purl.org/coar/resource_type/c_2df8fbb1AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/710495https://dx.doi.org/10.1016/j.bcp.2022.115078reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/7104952026-06-23T12:46:27Z
dc.title.none.fl_str_mv Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
title Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
spellingShingle Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
Shamoon, Licia
Resolvin E1
endothelial senescence
NLRP3 inflammasome
doxorubicin
interleukin 1β
vascular aging
Medicina
title_short Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
title_full Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
title_fullStr Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
title_full_unstemmed Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
title_sort Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation
dc.creator.none.fl_str_mv Shamoon, Licia
Espitia-Corredor, Jenaro A.
Dongil, Pilar
Menéndez Ribes, Marta
Romero, Alejandra
Valencia Fernández, Inés
Díaz-Araya, Guillermo
Sánchez Ferrer, Carlos Félix
Peiró Vallejo, M. Concepción
author Shamoon, Licia
author_facet Shamoon, Licia
Espitia-Corredor, Jenaro A.
Dongil, Pilar
Menéndez Ribes, Marta
Romero, Alejandra
Valencia Fernández, Inés
Díaz-Araya, Guillermo
Sánchez Ferrer, Carlos Félix
Peiró Vallejo, M. Concepción
author_role author
author2 Espitia-Corredor, Jenaro A.
Dongil, Pilar
Menéndez Ribes, Marta
Romero, Alejandra
Valencia Fernández, Inés
Díaz-Araya, Guillermo
Sánchez Ferrer, Carlos Félix
Peiró Vallejo, M. Concepción
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Farmacología
Facultad de Medicina
dc.subject.none.fl_str_mv Resolvin E1
endothelial senescence
NLRP3 inflammasome
doxorubicin
interleukin 1β
vascular aging
Medicina
topic Resolvin E1
endothelial senescence
NLRP3 inflammasome
doxorubicin
interleukin 1β
vascular aging
Medicina
description Endothelial cell senescence contributes to chronic inflammation and endothelial dysfunction, while favoring cardiovascular disorders and frailty. Senescent cells acquire a pro-inflammatory secretory phenotype that further propagates inflammation and senescence to neighboring cells. Cell senescence can be provoked by plethora of stressors, including inflammatory molecules and chemotherapeutic drugs. Doxorubicin (Doxo) is a powerful anthracycline anticancer drug whose clinical application is constrained by a dose-limiting cardiovascular toxicity. We here investigated whether cell senescence can contribute to the vascular damage elicited by Doxo. In human umbilical vein endothelial cells (HUVEC) cultures, Doxo (10–100 nM) increased the number of SA-β-gal positive cells and the levels of γH2AX, p21 and p53, used as markers of senescence. Moreover, we identified Doxo-induced senescence to be mediated by the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome, a key player of the immune innate system capable of releasing interleukin (IL)-1β. In fact, IL-1β itself mimicked the stimulatory action of Doxo on both NLRP3 activation and cellular senescence, while the pharmacological blockade of IL-1 receptors markedly attenuated the pro-senescence effects of Doxo. In search of additional pharmacological strategies to attenuate Doxo-induced endothelial senescence, we identified resolvin E1 (RvE1), an endogenous pro-resolving mediator, as capable of reducing cell senescence induced by both Doxo and IL-1β by interfering with the increased expression of pP65, NLRP3, and pro-IL-1β proteins and with the formation of active NLRP3 inflammasome complexes. Overall, RvE1 and the blockade of the NLRP3 inflammasome-IL-1β axis may offer a novel therapeutic approach against Doxo-induced cardiovascular toxicity and subsequent sequelae
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-05-10
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
AM
http://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/710495
https://dx.doi.org/10.1016/j.bcp.2022.115078
url http://hdl.handle.net/10486/710495
https://dx.doi.org/10.1016/j.bcp.2022.115078
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412396327501824
score 15,300724